Literature DB >> 19364852

Early- and late-onset pneumonia: is this still a useful classification?

Petra Gastmeier1, Dorit Sohr, Christine Geffers, Henning Rüden, Ralf-Peter Vonberg, Tobias Welte.   

Abstract

The choice of empirical treatment of nosocomial pneumonia in the intensive-care unit (ICU) used to rely on the interval after the start of mechanical ventilation. Nowadays, however, the question of whether in fact there is a difference in the distribution of causative pathogens is under debate. Data from 308 ICUs from the German National Nosocomial Infection Surveillance System, including information on relevant pathogens isolated in 11,285 cases of nosocomial pneumonia from 1997 to 2004, were used for our evaluation. Each individual pneumonia case was allocated either to early- or to late-onset pneumonia, with three differentiation criteria: onset on the 4th day, the 5th day, or the 7th day in the ICU. The frequency of pathogens was evaluated according to these categories. A total of 5,066 additional cases of pneumonia were reported from 2005 to 2006, after the CDC criteria had been modified. From 1997 to 2004, the most frequent microorganisms were Staphylococcus aureus (2,718 cases, including 720 with methicillin [meticillin]-resistant S. aureus), followed by Pseudomonas aeruginosa (1,837 cases), Klebsiella pneumoniae (1,305 cases), Escherichia coli (1,137 cases), Enterobacter spp. (937 cases), streptococci (671 cases), Haemophilus influenzae (509 cases), Acinetobacter spp. (493 cases), and Stenotrophomonas maltophilia (308 cases). The order of the four most frequent pathogens (accounting for 53.7% of all pathogens) was the same in both groups and was independent of the cutoff categories applied: S. aureus was first, followed by P. aeruginosa, K. pneumoniae, and E. coli. Thus, the predictabilities of the occurrence of pathogens were similar for the earlier (1997-to-2004) and later (2005-to-2006) time frames. This classification is no longer helpful for empirical antibiotic therapy, since the pathogens are the same for both groups.

Entities:  

Mesh:

Year:  2009        PMID: 19364852      PMCID: PMC2704703          DOI: 10.1128/AAC.01070-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria.

Authors:  Elpis Giantsou; Nikolaos Liratzopoulos; Eleni Efraimidou; Maria Panopoulou; Eleonora Alepopoulou; Sofia Kartali-Ktenidou; George I Minopoulos; Spyros Zakynthinos; Konstantinos I Manolas
Journal:  Intensive Care Med       Date:  2005-09-07       Impact factor: 17.440

2.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

Review 3.  Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

4.  Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.

Authors:  J L Trouillet; J Chastre; A Vuagnat; M L Joly-Guillou; D Combaux; M C Dombret; C Gibert
Journal:  Am J Respir Crit Care Med       Date:  1998-02       Impact factor: 21.405

5.  The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group.

Authors:  D K Heyland; D J Cook; L Griffith; S P Keenan; C Brun-Buisson
Journal:  Am J Respir Crit Care Med       Date:  1999-04       Impact factor: 21.405

6.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

7.  Pneumonia in intubated trauma patients. Microbiology and outcomes.

Authors:  A M Baker; J W Meredith; E F Haponik
Journal:  Am J Respir Crit Care Med       Date:  1996-01       Impact factor: 21.405

8.  National nosocomial infections surveillance system (NNIS): description of surveillance methods.

Authors:  T G Emori; D H Culver; T C Horan; W R Jarvis; J W White; D R Olson; S Banerjee; J R Edwards; W J Martone; R P Gaynes
Journal:  Am J Infect Control       Date:  1991-02       Impact factor: 2.918

9.  Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group.

Authors:  F Alvarez-Lerma
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

10.  Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial.

Authors:  G Prod'hom; P Leuenberger; J Koerfer; A Blum; R Chiolero; M D Schaller; C Perret; O Spinnler; J Blondel; H Siegrist; L Saghafi; D Blanc; P Francioli
Journal:  Ann Intern Med       Date:  1994-04-15       Impact factor: 25.391

View more
  16 in total

Review 1.  [Severe community-acquired and hospital-acquired pneumonia].

Authors:  L Witte; D Drömann
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-11       Impact factor: 0.840

2.  Characterization of Enterobacter cloacae pneumonia: a single-center retrospective analysis.

Authors:  Jan K Hennigs; Hans Jörg Baumann; Stefan Schmiedel; Pierre Tennstedt; Ingo Sobottka; Carsten Bokemeyer; Stefan Kluge; Hans Klose
Journal:  Lung       Date:  2011-10-19       Impact factor: 2.584

Review 3.  [Nosocomial pneumonia. Prevention and diagnostic].

Authors:  T Perl; M Quintel
Journal:  Anaesthesist       Date:  2011-03       Impact factor: 1.041

4.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

5.  Microbial profile of early and late onset ventilator associated pneumonia in the intensive care unit of a tertiary care hospital in bangalore, India.

Authors:  Saroj Golia; Sangeetha K T; Vasudha C L
Journal:  J Clin Diagn Res       Date:  2013-11-10

Review 6.  [Antibiotic treatment of nosocomial pneumonia].

Authors:  S Weiterer; D Störzinger; M Bernhard; K Mayer; C Lass-Flörl; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2011-03       Impact factor: 1.041

7.  [Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)].

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

8.  Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)).

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Ger Med Sci       Date:  2010-06-28

9.  Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial.

Authors:  Bruno François; Emmanuelle Mercier; Céline Gonzalez; Karim Asehnoune; Saad Nseir; Maud Fiancette; Arnaud Desachy; Gaëtan Plantefève; Ferhat Meziani; Paul-André de Lame; Pierre-François Laterre
Journal:  Intensive Care Med       Date:  2018-10-21       Impact factor: 17.440

10.  Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment.

Authors:  Gilles Capellier; Hélène Mockly; Claire Charpentier; Djillali Annane; Gilles Blasco; Thibault Desmettre; Antoine Roch; Christophe Faisy; Joel Cousson; Samuel Limat; Mariette Mercier; Laurent Papazian
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.